I have written twice on bladder cancer-focused enGene Holdings Inc. ( ENGN ), both times with substantial optimism about the investment thesis relative to their then-current market valuation. For the most part, 2025I have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls o ...